Chemical formula: C₂₈H₂₇N₃O₃ Molecular mass: 453.542 g/mol
Netarsudil, a Rho kinase inhibitor, is believed to reduce intraocular pressure (IOP) by increasing outflow of aqueous humor. Studies in animal and man suggest that the main mechanism of action is increased trabecular outflow. These studies also suggest that netarsudil lowers IOP by reducing episcleral venous pressure.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| S01EX05 | S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EX Other antiglaucoma preparations | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| RHOPRESSA Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RHOKIINSA Eye drops, solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Netarsudil is an active ingredient of these brands:
United States (US)
France (FR)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
